NORGESTIMATE AND ETHINYL ESTRADIOL

Post-LOE

norgestimate and ethinyl estradiol

Inpharmus

ANDAORAL-28TABLET

Approved

Jun 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NORGESTIMATE AND ETHINYL ESTRADIOL (norgestimate and ethinyl estradiol) by Inpharmus is ovulation. Approved for moderate acne vulgaris in females at least 15 years of age. First approved in 2012.

Drug data last refreshed 22h ago

Mechanism of Action

ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Indications (1)

moderate acne vulgaris in females at least 15 years of age

Company

Worked on NORGESTIMATE AND ETHINYL ESTRADIOL at Inpharmus? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.